companies

Carthera

Founded 2010
Employees 15+
Primary contact
Pépinière Paris Santé Cochin
29 rue du Faubourg Saint Jacques
75014 Paris
France
Links
https://carthera.eu/
Sections
A spin-off from AP-HP Paris and Sorbonne University, Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of brain disorders. It leverages the inventions of Pr. Alexandre Carpentier, head neurosurgeon at AP-HP Sorbonne University, who has achieved worldwide recognition for his innovative developments in treating brain disorders. Carthera is developing SonoCloud, an intracranial implant that temporarily opens the Blood-Brain Barrier (BBB). The device is currently in clinical trials in Europe and the United States. The company has offices in France (Lyon and Paris) and a subsidiary in the United States.
Select partners: Lantheus, KIYATEC.
Founded 2010
Employees 15+
Primary contact
Pépinière Paris Santé Cochin
29 rue du Faubourg Saint Jacques
75014 Paris
France
Links
https://carthera.eu/
Sections

Funding 💰

Total €66.8M
Last round 🔗 €37.5M
Series B
June 27, 2023.
Select investors European Innovation Council, Bpifrance, National Institutes of Health, French National Research Agency (ANR), Agoranov, Sham Innovation Santé, Panakes Partners, Supernova Invest, Groupe Arnault

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Unlocking therapeutic efficacies: The blood-brain barrier (BBB) blocks the penetration, and thus potential therapeutic effects, of over 95% of small molecule and 100% of large molecule drugs in the brain. SonoCloud uses the therapeutic potential of pulsed ultrasound to temporarily disrupt the BBB. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases.
  • Several versions of SonoCloud: Carthera has developed several versions of SonoCloud, including the SonoCloud-1 and SonoCloud-9 devices. These MRI-compatible devices are designed to disrupt large regions of the blood-brain barrier (BBB) to increase the therapeutic efficacy of drugs in targeted brain regions and are currently in clinical trials for glioblastoma, brain metastases, and Alzheimer's Disease. 🔗
  • Clinical pipeline: Carthera's priority is to develop therapeutic approaches that will benefit patients with high unmet needs. With its partnered institutions, the company is addressing neuro-oncological indications with adult and pediatric glioblastoma and brain metastases trials, as well as neuro-degenerative indications with a trial in Alzheimer's Disease. 🔗

Video ▶️

In the news 📰

Carthera raises €37.5M in Series B funding round
June 27, 2023

Quotes 💬

“
We are pleased to continue supporting Carthera in its next step towards its first pivotal trial in recurrent glioblastoma, since the initial results have been very positive in this indication. We also believe its ultrasound-based platform technology has the potential to address many of the most challenging therapeutic indications in the neurodegenerative field. We are very proud to be part of this journey.
— Diana Saraceni, founder and managing partner at Panakès 🔗
Last update: July 4, 2023